Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 13/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 6/20 | 0.43 |
| ▸ | CDK1 | P06493 | 8/20 | 0.38 |
| ▸ | JAK2 | O60674 | 2/20 | 0.36 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.36 |
| ▸ | CDK4 | P11802 | 1/20 | 0.36 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.36 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.36 |
| ▸ | JAK1 | P23458 | 1/20 | 0.35 |
| ▸ | JAK3 | P52333 | 1/20 | 0.35 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14092821 | 0.91 | CDK2 (0.46) | CDK2KCNH2CDK1JAK2CDK4 | |
| SCHEMBL4435674 | 0.90 | CDK2 (0.49) | CDK2KCNH2CDK1JAK2CDK4 | |
| SCHEMBL4433038 | 0.90 | CDK2 (0.49) | CDK2KCNH2CDK1JAK2CDK4 | |
| SCHEMBL4434460 | 0.89 | CDK2 (0.48) | CDK2KCNH2CDK1JAK2CDK4 | |
| SCHEMBL4430574 | 0.88 | CDK2 (0.49) | CDK2KCNH2CDK1JAK2CDK4 | |
| SCHEMBL3939760 | 0.88 | CDK2 (0.51) | CDK2KCNH2CDK1JAK2CDK4 | |
| SCHEMBL4432737 | 0.86 | CDK2 (0.45) | CDK2KCNH2CDK1CDK4 | |
| SCHEMBL4436531 | 0.85 | CDK2 (0.47) | CDK2KCNH2CDK1JAK2CDK4 | |
| SCHEMBL4430807 | 0.85 | CDK2 (0.45) | CDK2KCNH2CDK1 | |
| SCHEMBL4438545 | 0.84 | CDK2 (0.44) | CDK2KCNH2CDK1JAK2CDK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080188503-A1 | 5-Fluoro-4-[2-methyl-1-(tetrahydro-2H-pyran-4-yl)-1H-imidazol-5-yl]-N-pyrimidin-5-ylpyrimidin-2-amine; Alzheimer's Disease (AD) Dementias, and Taupathies; GSK3 inhibitors in inflammatory diseases | ASTRAZENACA AB (SE) | 2008-08-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080188503-A1 | 5-Fluoro-4-[2-methyl-1-(tetrahydro-2H-pyran-4-yl)-1H-imidazol-5-yl]-N-pyrimidin-5-ylpyrimidin-2-amine; Alzheimer's Disease (AD) Dementias, and Taupathies; GSK3 inhibitors in inflammatory diseases | GSK3B, GSK3A, MAPT | CDK2 328/4885KCNH2 3601/4885CDK1 145/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.